Benjamin Eckhardt received his MD degree from Albert Einstein College of Medicine, and Internal Medicine training at NYU within the Primary Care Program. After completing residency, he worked in Rwanda for Partners in Health/Inshuti Mu Buzima with a clinical appointment at Brigham and Women’s Hospital and Harvard Medical School. He returned to New York to complete his fellowship training in Infectious Diseases at Weill Cornell Medical College while concurrently receiving a MS in Clinical Epidemiology and Health Services Research. He joined the faculty at NYU/Bellevue in 2016 with a clinical focus in HIV and hepatitis management. Benjamin’s research interests focus on evaluating models of care to facilitate access, engagement, and retention of active injection drug users in HCV treatment and care.
At the completion of this educational session, learners will:
- Know the epidemiology of HCV and HCV/HIV coinfection in injection drug users.
- Be aware of unique challenges in treating HCV in PWID.
- Appreciate HCV clinical trial treatment data including PWID.
- Understand current policy around HCV treatment in PWID.
This CME activity was approved for AMA PRA Category 1 Credit™
on May 15, 2018 and will terminate May 14, 2021.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. Benjamin Eckhardt (Presenter) had the following personal financial relationships in the prior 12 months with manufacturers of the products or services that may be presented in this CME activity: Grant/research support recipient from Gilead; and Bristol-Myers Squibb. Dr. Eckhardt submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences, Janssen Therapeutics (a division of Janssen Products, LP), Merck & Co., and ViiV Healthcare.
To obtain CME credit for this PRN program, please visit the PRN Courses Page
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.